Literature DB >> 27553362

Intramyocardial Gene Therapy Directed to Hibernating Heart Muscle Using a Combination of Electromechanical Mapping and Positron Emission Tomography.

Iiro Hassinen1, Antti Kivelä1, Antti Hedman1, Antti Saraste2, Juhani Knuuti2, Juha Hartikainen1,3, Seppo Ylä-Herttuala1,4,5.   

Abstract

Cardiac gene transfer for the treatment of ischemic diseases has suffered from low gene transfer efficiency and inability to target treatment genes to the ischemic myocardium. A combined method has been developed based on electromechanical mapping and radiowater PET imaging to target gene therapy to viable but ischemic and hibernating areas of the myocardium. Electromechanical NOGA mapping produces three-dimensional images of myocardium with both an electric activity map and a myocardial contractility map. These have been converted to 17-segment 2D bull's-eye maps, which were superimposed onto PET radiowater perfusion imaging maps of the myocardium. This technique was applied in a Phase I/IIa clinical trial to target gene therapy for refractory angina patients. It was found that by combining electromechanical map with PET imaging, targeting of gene therapy to hibernating ischemic myocardium can be significantly improved. Here, the methods for the identification of viable, ischemic, and hibernating myocardium for gene transfer are described, and examples of treated refractory angina patients who have benefited from the improved gene transfer method to the ischemic myocardium are presented.

Entities:  

Mesh:

Year:  2016        PMID: 27553362     DOI: 10.1089/hum.2016.131

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  7 in total

1.  Protection of coronary circulation: Evaluation by PET perfusion imaging.

Authors:  Antti Saraste; Heikki Ukkonen; Juhani Knuuti
Journal:  J Nucl Cardiol       Date:  2017-01-03       Impact factor: 5.952

Review 2.  Future directions for therapeutic strategies in post-ischaemic vascularization: a position paper from European Society of Cardiology Working Group on Atherosclerosis and Vascular Biology.

Authors:  Andrea Caporali; Magnus Bäck; Mat J Daemen; Imo E Hoefer; Elizabeth A Jones; Esther Lutgens; Christian M Matter; Marie-Luce Bochaton-Piallat; Arndt F Siekmann; Judith C Sluimer; Sabine Steffens; José Tuñón; Cecile Vindis; Jolanda J Wentzel; Seppo Ylä-Herttuala; Paul C Evans
Journal:  Cardiovasc Res       Date:  2018-09-01       Impact factor: 10.787

Review 3.  Lymphangiogenesis: fuel, smoke, or extinguisher of inflammation's fire?

Authors:  Gabriella R Abouelkheir; Bradley D Upchurch; Joseph M Rutkowski
Journal:  Exp Biol Med (Maywood)       Date:  2017-03-07

Review 4.  Cardiovascular Gene Therapy: Past, Present, and Future.

Authors:  Seppo Ylä-Herttuala; Andrew H Baker
Journal:  Mol Ther       Date:  2017-04-04       Impact factor: 11.454

5.  Cell-Based HIF1α Gene Therapy Reduces Myocardial Scar and Enhances Angiopoietic Proteome, Transcriptomic and miRNA Expression in Experimental Chronic Left Ventricular Dysfunction.

Authors:  Edit Gara; Sang-Ging Ong; Johannes Winkler; Katrin Zlabinger; Dominika Lukovic; Bela Merkely; Maximilian Y Emmert; Petra Wolint; Simon P Hoerstrup; Mariann Gyöngyösi; Joseph C Wu; Noemi Pavo
Journal:  Front Bioeng Biotechnol       Date:  2022-05-12

6.  Comparison of Efficiency and Function of Vascular Endothelial Growth Factor Adenovirus Vectors in Endothelial Cells for Gene Therapy of Placental Insufficiency.

Authors:  Carlo Rossi; Mark Lees; Vedanta Mehta; Tommi Heikura; John Martin; Ian Zachary; Rebecca Spencer; Donald M Peebles; Robert Shaw; Minna Karhinen; Seppo Yla-Herttuala; Anna L David
Journal:  Hum Gene Ther       Date:  2020-11       Impact factor: 5.695

7.  Long-term safety and efficacy of intramyocardial adenovirus-mediated VEGF-DΔNΔC gene therapy eight-year follow-up of phase I KAT301 study.

Authors:  Aleksi J Leikas; Iiro Hassinen; Antti Hedman; Antti Kivelä; Seppo Ylä-Herttuala; Juha E K Hartikainen
Journal:  Gene Ther       Date:  2021-10-01       Impact factor: 4.184

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.